Araştırma Makalesi
PDF Zotero Mendeley EndNote BibTex Kaynak Göster

Single-center Experience in Relapsed / REFRACTORY NON-HODGKIN’S lymphoma

Yıl 2022, Cilt 44, Sayı 1, 51 - 56, 30.03.2022
https://doi.org/10.7197/cmj.1079526

Öz

Non-Hodgkin’s lymphomas are a heterogeneous malignancy group originating from lymphoid tissue and having an increasing frequency in the world in the last decade. Its clinic and response to treatment vary according to different sub-types. Today, the most compelling situation for a clinician is the patients with relapsed or refractory Non-Hodgkin’s lymphoma. Its prognosis is poor even despite different treatments and autologous stem cell transplantation. The aim of the present study is to present the experiences in the diagnosis of relapsed/refractory Non-Hodgkin’s lymphoma to the literature. A total of 193 patients, who were diagnosed and treated at Sivas Cumhuriyet University Medical Faculty Hospital between 2011 and 2021 were included in the study. 145 of these patients were not relapsed/refractory and 48 were relapsed/refractory. Rescue therapy was provided to the relapsed/refractory patients; however, autologous stem cell transplantation could only be applied to 25 patients. Of the stem cell transplantation patients, 17 are still alive. As a result, the best treatment under current conditions is the rescue therapy, followed by autologous stem cell transplantation. However, relapsed/refractory Non-Hodgkin’s lymphomas have a quite poor prognosis; thus, new treatment agents are required.

Kaynakça

  • 1. Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 174–179.
  • 2. Moubadder L, McCullough LE, Flowers CR, Koff JL. Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiol Biomarkers Prev. 2020; 29(10): 1844–1855. doi: 10.1158/1055-9965.EPI-20-0228.
  • 3. Younes A, Salles G, Martinelli G, Bociek RG, Barrigon DC, Barca EG, et al. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 2017; 102(12): 2104–2112. doi: 10.3324/haematol.2017.169656.
  • 4. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G. International Non-Hodgkin’s Lymphoma Prognostic factors Project. A Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med1993; 329: 987-994.
  • 5. Schmıtt M, Trenschel R, Sayer HG, Schneıder C, Glass A, Hılgendorf I, et al. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non‑Hodgkin lymphoma. Molecular and Clınıcal Oncology 2013; 2: 773-782.
  • 6. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. The lancet 2017; 390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2
  • 7. Demir D, Özsan N, Demir E, Arslan A, Davulcu EA, Soyer NA, et al. Retrospective evaluation of the epidemiological and overall survival characteristics of adult non-Hodgkin lymphoma cases registered to Ege University Hospital database Ege Tıp Dergisi / Ege Journal of Medicine 2020; 59: Ek Sayı /Supplement 66-78.
  • 8. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision to the World Health Organization classification of lymphoid neoplasm. Blood 2016; 127, 2375–2390.
  • 9. Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res 2019; 19:645–661.
  • 10. Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, et al. Phase I/II Study of Dasatinib and Exploratory Genomic Analysis in Relapsed or Refractory Non-Hodgkin Lymphoma. Br J Haematol 2019; 184(5): 744–752. doi: 10.1111/bjh.15702.
  • 11. Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB, Parihar AS, et al. Non-Hodgkin's lymphoma: A review. J Family Med Prim Care 2020; 9(4): 1834–1840. doi: 10.4103/jfmpc.jfmpc_1037_19.
  • 12. Yiwei L, Pengfei S, Yaping X, Shenxian Q. Serum uric acid level is a prognostic indicator and improves the predictive ability of the IPI score in diffuse large B-cell lymphoma Int J Clin Exp Med 2018; 11(3): 2223-223.
  • 13. Lee SJ, Suh CW, Lee SII, Kim WS, Lee WS, Kim HJ, et al. The Consortium for Improving Survival of Lymphoma. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. Korean J Intern Med 2014; 29(3): 352–360. doi: 10.3904/kjim.2014.29.3.352.
  • 14. Lee SJ, Suh CW, Lee SI, Kim WS, Lee WS, Kim HJ, et al. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer’s ring: nationwide Korean study. Korean J Intern Med 2014; 29:352-360. Doi:10.3904/kjim.2014.29.3.352.
  • 15. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28, 4184–4190.
  • 16. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 15;20(24):4643-8. doi: 10.1200/JCO.2002.11.013.

Yıl 2022, Cilt 44, Sayı 1, 51 - 56, 30.03.2022
https://doi.org/10.7197/cmj.1079526

Öz

Kaynakça

  • 1. Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 174–179.
  • 2. Moubadder L, McCullough LE, Flowers CR, Koff JL. Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiol Biomarkers Prev. 2020; 29(10): 1844–1855. doi: 10.1158/1055-9965.EPI-20-0228.
  • 3. Younes A, Salles G, Martinelli G, Bociek RG, Barrigon DC, Barca EG, et al. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 2017; 102(12): 2104–2112. doi: 10.3324/haematol.2017.169656.
  • 4. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G. International Non-Hodgkin’s Lymphoma Prognostic factors Project. A Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med1993; 329: 987-994.
  • 5. Schmıtt M, Trenschel R, Sayer HG, Schneıder C, Glass A, Hılgendorf I, et al. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non‑Hodgkin lymphoma. Molecular and Clınıcal Oncology 2013; 2: 773-782.
  • 6. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. The lancet 2017; 390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2
  • 7. Demir D, Özsan N, Demir E, Arslan A, Davulcu EA, Soyer NA, et al. Retrospective evaluation of the epidemiological and overall survival characteristics of adult non-Hodgkin lymphoma cases registered to Ege University Hospital database Ege Tıp Dergisi / Ege Journal of Medicine 2020; 59: Ek Sayı /Supplement 66-78.
  • 8. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision to the World Health Organization classification of lymphoid neoplasm. Blood 2016; 127, 2375–2390.
  • 9. Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res 2019; 19:645–661.
  • 10. Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, et al. Phase I/II Study of Dasatinib and Exploratory Genomic Analysis in Relapsed or Refractory Non-Hodgkin Lymphoma. Br J Haematol 2019; 184(5): 744–752. doi: 10.1111/bjh.15702.
  • 11. Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB, Parihar AS, et al. Non-Hodgkin's lymphoma: A review. J Family Med Prim Care 2020; 9(4): 1834–1840. doi: 10.4103/jfmpc.jfmpc_1037_19.
  • 12. Yiwei L, Pengfei S, Yaping X, Shenxian Q. Serum uric acid level is a prognostic indicator and improves the predictive ability of the IPI score in diffuse large B-cell lymphoma Int J Clin Exp Med 2018; 11(3): 2223-223.
  • 13. Lee SJ, Suh CW, Lee SII, Kim WS, Lee WS, Kim HJ, et al. The Consortium for Improving Survival of Lymphoma. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. Korean J Intern Med 2014; 29(3): 352–360. doi: 10.3904/kjim.2014.29.3.352.
  • 14. Lee SJ, Suh CW, Lee SI, Kim WS, Lee WS, Kim HJ, et al. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer’s ring: nationwide Korean study. Korean J Intern Med 2014; 29:352-360. Doi:10.3904/kjim.2014.29.3.352.
  • 15. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28, 4184–4190.
  • 16. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 15;20(24):4643-8. doi: 10.1200/JCO.2002.11.013.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Dahili Tıp Bilimleri Araştırma Yazıları
Yazarlar

Hatice TERZİ (Sorumlu Yazar)
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0003-3471-1305
Palestine, State of


Kübra ORAL
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0001-6461-5811
Türkiye


Hüseyin YILMAZ
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0002-3387-7920
Türkiye


Ecem DEMİR YURTSEVEN
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0001-9714-0672
Türkiye


Mehmet ŞENCAN
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0002-1459-3906
Türkiye

Yayımlanma Tarihi 30 Mart 2022
Yayınlandığı Sayı Yıl 2022, Cilt 44, Sayı 1

Kaynak Göster

APA Terzi, H. , Oral, K. , Yılmaz, H. , Demir Yurtseven, E. & Şencan, M. (2022). Single-center Experience in Relapsed / REFRACTORY NON-HODGKIN’S lymphoma . Cumhuriyet Medical Journal , 44 (1) , 51-56 . DOI: 10.7197/cmj.1079526